Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 Combined With Pertuzumab in First-line HER2-positive Breast Cancer
NCT07518173Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in breast cancer, sponsored by Biokin Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07518173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518173.